DUFFY LB, CRABB D, WALL W, HERRINGTON JA; Interscience Conference on Antimicrobial Agents and Chemotherapy.

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1999 Sep 26-29; 39: 252 (abstract no. 367).

Univ. of Alabama at Birmingham, Birmingham, AL

Mycoplasma pneumoniae is the leading cause of tracheobronchitis in school-aged children. In the general population, it accounts for 20% of all pneumonia and up to 50% in closed populations. Most mycoplasma infections are acute and self-limiting, however, M. pneumoniae can produce life threatening disease in all age groups. No strains of M. pneumoniae have been found to be resistant to erythromycin; its effectiveness is limited due to erratic absorption and gastrointestinal discomfort. This study compared the activity of a new 8-methoxyfluoroquinolone, moxifloxacin (MXF), against the newer macrolides and quinolones. A microbroth dilution method was used to test low-passaged clinical respiratory isolates from patients with radiographically proven cases of pneumonia. These isolates were identified by polymerase chain reaction (PCR) as M. pneumoniae and were not cross-reactive with other mycoplasma species found in the human respiratory or genital tract. The minimum inhibitory concentrations (MICs) are reported in microg/ml. MXF was extremely active against all 32 isolates. MIC[50]s were as follows: 0.031 for MXF, 0.125 for trovafloxacin (TVA) and grepafloxacin (GRX), 0.5 for levofloxacin (LVX), and Publication Types:

• Meeting Abstracts

Keywords:

• Anti-Bacterial Agents
• Anti-Infective Agents
• Aza Compounds
• Child
• Erythromycin
• Fluoroquinolones
• Humans
• In Vitro
• Macrolides
• Microbial Sensitivity Tests
• Mycoplasma
• Mycoplasma Infections
• Mycoplasma pneumoniae
• Naphthyridines
• Ofloxacin
• Pneumonia, Mycoplasma
• Quinolines
• Respiratory Tract Infections
• grepafloxacin
• moxifloxacin
• trovafloxacin

Other ID:

• GWAIDS0007870

UI: 102245367

From Meeting Abstracts